Article Information
History
- October 15, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Tinei Shamu1,2,3,*,
- Matthias Egger2,4,5,
- Tinashe Mudzviti1,6,
- Cleophas Chimbetete1,
- Justen Manasa7 and
- Nanina Anderegg1,4
- 1Newlands Clinic, Harare, Zimbabwe
- 2Institute of Social and Preventive Medicine, University of Bern, Switzerland
- 3Graduate School of Health Sciences, University of Bern, Switzerland
- 4Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa
- 5Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 6Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare, Zimbabwe
- 7Innovation Hub, University of Zimbabwe, Harare, Zimbabwe
- ↵*Corresponding Author E-mail: tineis{at}newlandsclinic.org.zw (TS)
Posted October 15, 2023.
Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study
